REKA Stock Overview
Engages in the manufacture, marketing, sale, and distribution of prescription and OTC drugs, dermo-cosmetics, vitamins, and nutritional supplements in Israel. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rekah Pharmaceutical Industry Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪14.29 |
| 52 Week High | ₪16.79 |
| 52 Week Low | ₪11.67 |
| Beta | 0.055 |
| 11 Month Change | 2.88% |
| 3 Month Change | 5.07% |
| 1 Year Change | -7.75% |
| 33 Year Change | -38.48% |
| 5 Year Change | -31.20% |
| Change since IPO | -95.92% |
Recent News & Updates
Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Shares Climb 30% But Its Business Is Yet to Catch Up
Jul 11
Here's Why Rekah Pharmaceutical Industry (TLV:REKA) Has A Meaningful Debt Burden
Jul 05Recent updates
Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Shares Climb 30% But Its Business Is Yet to Catch Up
Jul 11Here's Why Rekah Pharmaceutical Industry (TLV:REKA) Has A Meaningful Debt Burden
Jul 05Here's Why Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) CEO May Not Expect A Pay Rise This Year
Dec 14Rekah Pharmaceutical Industry (TLV:REKA) Has A Somewhat Strained Balance Sheet
Sep 12Estimating The Fair Value Of Rekah Pharmaceutical Industry Ltd. (TLV:REKA)
Jul 19Rekah Pharmaceutical Industry's (TLV:REKA) Problems Go Beyond Weak Profit
Apr 13We Think Rekah Pharmaceutical Industry (TLV:REKA) Is Taking Some Risk With Its Debt
May 12Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Might Deserve Your Attention Today
Apr 09Does Rekah Pharmaceutical Industry's (TLV:REKA) Share Price Gain of 50% Match Its Business Performance?
Mar 12Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Feb 19
Is Rekah Pharmaceutical Industry (TLV:REKA) Using Too Much Debt?
Jan 29Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Is An Interesting Stock
Jan 08How Is Rekah Pharmaceutical Industry's (TLV:REKA) CEO Paid Relative To Peers?
Dec 18Investors Who Bought Rekah Pharmaceutical Industry (TLV:REKA) Shares Five Years Ago Are Now Up 33%
Nov 30Shareholder Returns
| REKA | IL Pharmaceuticals | IL Market | |
|---|---|---|---|
| 7D | -3.5% | 1.8% | 1.0% |
| 1Y | -7.7% | -4.7% | 26.0% |
Return vs Industry: REKA matched the IL Pharmaceuticals industry which returned -7.8% over the past year.
Return vs Market: REKA underperformed the IL Market which returned 26.9% over the past year.
Price Volatility
| REKA volatility | |
|---|---|
| REKA Average Weekly Movement | 4.8% |
| Pharmaceuticals Industry Average Movement | 6.3% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in IL Market | 7.2% |
| 10% least volatile stocks in IL Market | 2.9% |
Stable Share Price: REKA has not had significant price volatility in the past 3 months compared to the IL market.
Volatility Over Time: REKA's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1941 | 427 | Mordechai Elgrabli | www.rekah.co.il |
Rekah Pharmaceutical Industry Ltd. engages in the manufacture, marketing, sale, and distribution of prescription and OTC drugs, dermo-cosmetics, vitamins, and nutritional supplements in Israel. The company offers steroid tablets; antibiotics, including penicillin and cephalosporin; drops and ointments to treat allergies, infections, and dryness of the eyes; baby products; and dermatological preparations. Its portfolio of products comprise approximately 280 drugs used in various medical fields.
Rekah Pharmaceutical Industry Ltd. Fundamentals Summary
| REKA fundamental statistics | |
|---|---|
| Market cap | ₪163.12m |
| Earnings (TTM) | ₪6.81m |
| Revenue (TTM) | ₪324.36m |
24.0x
P/E Ratio0.5x
P/S RatioIs REKA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| REKA income statement (TTM) | |
|---|---|
| Revenue | ₪324.36m |
| Cost of Revenue | ₪248.92m |
| Gross Profit | ₪75.45m |
| Other Expenses | ₪68.64m |
| Earnings | ₪6.81m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.60 |
| Gross Margin | 23.26% |
| Net Profit Margin | 2.10% |
| Debt/Equity Ratio | 55.6% |
How did REKA perform over the long term?
See historical performance and comparison